Insuman Comb 50 (Insulin Human)

Insulin human mimics the body’s natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular signaling that moves glucose‑transport proteins to the cell surface, promotes glycogen synthesis, suppresses hepatic glucose production, and facilitates overall glucose uptake, thereby lowering blood‑sugar concentrations.

The dose of Insuman Comb 50 is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s current blood‑glucose readings, carbohydrate intake, body weight, renal function, and response to previous insulin therapy. Patients should follow the prescriber’s instructions and regularly monitor glucose levels.

Human insulin is classified as a pregnancy‑category drug only when the benefits to the mother outweigh potential risks to the fetus. Insuman Comb 50 may be used during pregnancy or lactation under close medical supervision. The prescribing clinician will assess individual circumstances and adjust therapy as needed.

To request Insuman Comb 50, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and the necessary import documentation.

Insuman Comb 50 contains human insulin, which has a well‑established safety profile and provides both basal and prandial coverage. Compared with rapid‑acting insulin analogues, it may have a slightly slower onset but a longer duration of action. It is generally less expensive than many analogues, making it a cost‑effective option for many treatment regimens.

Insuman Comb 50 should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a limited period, as indicated on the label, but should not be shaken vigorously.

Insuman Comb 50 is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce lipodystrophy. Patients or caregivers should use a sterile needle, follow aseptic technique, and inject at a 90‑degree angle into the fatty tissue. Dosing times are usually coordinated with meals and bedtime as directed by the prescriber.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical help if a severe reaction occurs. Regular monitoring and prompt dose adjustments are essential to mitigate these risks.

Insuman Comb 50 is contraindicated in individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It should also be avoided in patients experiencing hypoglycemia until glucose levels are normalized. Caution is advised for patients with severe renal or hepatic impairment, and the drug should be used only under medical supervision in such cases.